Work

Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.tps3102

Authors: Melinda S. Merchant, Mihaela C. Cristea, Edward A. Stadtmauer, William D. Tap, Sandra P. D'Angelo, Stephan A. Grupp, Tom Holdich, Gwendolyn Binder-Scholl, Bent K Jakobsen, Kunle Odunsi, Aaron Rapoport, Crystal Mackall

Institutions: National Cancer Institute, City Of Hope National Medical Center, City of Hope, Abramson Cancer Center, University of Pennsylvania, Memorial Sloan Kettering Cancer Center, Children's Hospital of Philadelphia, Adaptimmune (United Kingdom), Roswell Park Comprehensive Cancer Center, National Institutes of Health

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2472613419

Cites:

Cited by: 7

Related to: 10